Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review

Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

(2019) Louis P. Garrison et al.   VALUE IN HEALTH

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

(2019) Anne Julienne Genuino et al.   BMC HEALTH SERVICES RESEARCH

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Conditional disease-free survival among patients with breast cancer

(2017) Hyun-June Paik et al.   MEDICINE

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

(2017) Amir Ansaripour et al.   PHARMACOECONOMICS

A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

(2017) Daniel A. Goldstein et al.   Oncotarget

Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer

(2017) Henry W. C. Leung et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan

(2016) Hui-Chu Lang et al.   JOURNAL OF MEDICAL ECONOMICS

A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer

(2015) Vakaramoko Diaby et al.   BREAST CANCER RESEARCH AND TREATMENT

IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES

(2015) Andres Pichon-Riviere et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE

Challenges to effective cancer control in China, India, and Russia

(2014) Paul E Goss et al.   LANCET ONCOLOGY

Cost-Effectiveness Analysis of 1-Year Adjuvant Trastuzumab Therapy of Early-Stage Her2-Positive Breast Cancer

(2014) Nguyen TTC et al.   VALUE IN HEALTH

Cost-Utility Analysis of Trastuzumab in Treatment Of Metastatic Her2-Positive Breast Cancer in Vietnam

(2014) T.T.C. Nguyen et al.   VALUE IN HEALTH

Evaluación económica del trastuzumab como tratamiento adyuvante en cáncer de mama HER2-positivo en Colombia

(2013) Jefferson Antonio Buendía et al.   Biomedica

A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer

(2013) Ava A. John-Baptiste et al.   PLoS One

Breast cancer research in Asia: Adopt or adapt Western knowledge?

(2012) Nirmala Bhoo-Pathy et al.   EUROPEAN JOURNAL OF CANCER

Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer

(2010) Patricia R. Blank et al.   PHARMACOECONOMICS

Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review

(2009) Agnes LF Chan et al.   ANNALS OF PHARMACOTHERAPY

Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries

(2009) Ya-Chen Tina Shih et al.   PHARMACOECONOMICS

The Costs of Treating Breast Cancer in the US

(2009) Jonathan D. Campbell et al.   PHARMACOECONOMICS

Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil

(2009) Marcelo Fonseca et al.   Revista da Associacao Medica Brasileira

An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

(2009) Wen Chen et al.   VALUE IN HEALTH

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE